Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%

Shares of Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) were down 2.1% during mid-day trading on Wednesday . The stock traded as low as $0.64 and last traded at $0.69. Approximately 457,077 shares changed hands during trading, a decline of 55% from the average daily volume of 1,006,999 shares. The stock had previously closed at $0.71.

Petros Pharmaceuticals Stock Performance

The company has a quick ratio of 1.74, a current ratio of 1.89 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $1.36 and a 200-day simple moving average of $1.37. The company has a market cap of $4.74 million, a PE ratio of -0.11 and a beta of 1.91.

Petros Pharmaceuticals (NASDAQ:PTPI) last announced its quarterly earnings results on Monday, April 1st. The company reported ($2.17) EPS for the quarter. The firm had revenue of ($0.36) million for the quarter. Petros Pharmaceuticals had a negative return on equity of 68.90% and a negative net margin of 181.87%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in shares of Petros Pharmaceuticals during the 2nd quarter worth $34,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Petros Pharmaceuticals during the 2nd quarter worth $47,000. Virtu Financial LLC acquired a new stake in shares of Petros Pharmaceuticals during the 4th quarter worth $35,000. BlackRock Inc. increased its holdings in shares of Petros Pharmaceuticals by 880.2% during the 1st quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock worth $300,000 after buying an additional 172,156 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Petros Pharmaceuticals by 114.8% during the 3rd quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock worth $131,000 after buying an additional 136,773 shares during the last quarter. 12.34% of the stock is currently owned by institutional investors and hedge funds.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).